← Back to Clinical Trials
Recruiting NCT07133620

NCT07133620 the Effect of Transcutaneous Electrical Acupoint Stimulation on Postoperative Gastrointestinal Dysfunction After Urological Laparoscopic Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07133620
Status Recruiting
Phase
Sponsor The First Affiliated Hospital of Xiamen University
Condition Postoperative Gastrointestinal Dysfunction (POGD)
Study Type INTERVENTIONAL
Enrollment 112 participants
Start Date 2025-11-01
Primary Completion 2026-11-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Transcutaneous electrical acupoint stimulationSham transcutaneous Electrical Acupoint Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 112 participants in total. It began in 2025-11-01 with a primary completion date of 2026-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this clinical trial is to understand the effect of percutaneous acupoint electrical stimulation on postoperative gastrointestinal dysfunction. It will also investigate the safety of percutaneous acupoint electrical stimulation. The main questions that this trial aims to answer are: Can percutaneous acupoint electrical stimulation alleviate postoperative gastrointestinal dysfunction? Through which mechanisms do they function? Participants will: Preoperatively, patients were either given or not given percutaneous acupoint electrical stimulation. Record their symptoms and biological indicators within 5 days after the operation.

Eligibility Criteria

Inclusion Criteria: * Age \> 18 years * BMI \< 28 kg/m2 * ASA classification is I-III grade * Laparoscopic urological procedures under general anesthesia, including but not limited to laparoscopic nephrectomy and laparoscopic radical prostatectomy for prostate cancer * Normal comprehension ability, and the patient or his/her family members can cooperate in filling out the questionnaire * Voluntary to sign the informed consent form Exclusion Criteria: * Comprehensive assessment of severe cardiovascular, pulmonary and cerebrovascular diseases (such as severe coronary heart disease, valve diseases, respiratory failure, cerebral hemorrhage, cerebral infarction, etc.) * Preoperative use of analgesic and gastrointestinal motility drugs * TEAS contraindications (having electronic devices in the body, skin damage or infection at the stimulation site) * Previous history of TEAS or electro-acupuncture treatment * Previous history of gastrointestinal surgery, long-term gastrointestinal motility disorders and severe intestinal diseases * Pregnancy

Contact & Investigator

Central Contact

Linhong Wang

✉ 2797424071@qq.com

📞 +86-13807548496

Frequently Asked Questions

Who can join the NCT07133620 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Postoperative Gastrointestinal Dysfunction (POGD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07133620 currently recruiting?

Yes, NCT07133620 is actively recruiting participants. Contact the research team at 2797424071@qq.com for enrollment information.

Where is the NCT07133620 trial being conducted?

This trial is being conducted at Xiamen, China.

Who is sponsoring the NCT07133620 clinical trial?

NCT07133620 is sponsored by The First Affiliated Hospital of Xiamen University. The trial plans to enroll 112 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology